Advertisement
The Body: The Complete HIV/AIDS Resource
Follow Us Follow Us on Facebook Follow Us on Twitter Download Our App
Professionals >> Visit The Body PROThe Body en Espanol
   
Ask the Experts About

Choosing Your MedsChoosing Your Meds
           
Rollover images to visit our other forums!
Recent AnswersAsk a Question
  
  • Email Email
  • Glossary Glossary


Why All The Excitment About Entry Inhibitors?
Feb 27, 2002

Dr. Young: Hello. Why is there such excitement with entry inhibitors? Will T20 and T1249 later to be just as infective for many HIV infected as HAART has? Sorry if I sound too cynical, but the past is littered with much hearlded HIV "magic bullets" just to later proven inefective for many. What is your take on these drugs? Thanks for the excellent service you provide.

Response from Dr. Young

Anytime a new class of drugs shows promise, there is a lot of interest and excitement.

Such is the attention that entry inhibitors have received over the past several years. The first drugs of this class to see human trials were the inhibitors T-20 and T-1249. The former is now in phase III clinical trials and show considerable promise; as expected the compound retains activity among persons with resistance to currently approved drugs. These drugs may have a role in the treatment of persons with drug resistance, but the delivery of the drug is problematic, as it requires daily injections.

Other entry inhibitors have also been in the news of late, but are very early in drug development: SCH-C, an orally delivered entry inhibitor from Schering-Plough; AMD-3100 from AnorMED. Both drugs have been studied in a handful of HIV infected persons to date. Long-term antiviral effect and safety of these are yet to be fully established. Several other companies are also working on entry inhibitors and have compounds in the pre-clinical stage of development.

I agree that there are two many exciting preliminary stories about the next magic drug bullet for HIV treatment. We need to be patient for careful scientifically valid (and confirmed) observations before placing new drugs into the landscape of treatment options for persons with HIV. Rushing to judgement usally results in premature conclusions and false hopes. BY



Previous
Viral Loads - Length of Time to Drug Failure
Next
AZT monotherapy in 2001

  
  • Email Email
  • Glossary Glossary

 Get Email Notifications When This Forum Updates or Subscribe With RSS


 
Advertisement



Q&A TERMS OF USE

This forum is designed for educational purposes only, and experts are not rendering medical, mental health, legal or other professional advice or services. If you have or suspect you may have a medical, mental health, legal or other problem that requires advice, consult your own caregiver, attorney or other qualified professional.

Experts appearing on this page are independent and are solely responsible for editing and fact-checking their material. Neither TheBody.com nor any advertiser is the publisher or speaker of posted visitors' questions or the experts' material.

Review our complete terms of use and copyright notice.

Powered by ExpertViewpoint

Advertisement